Inhibition of CDK2 in melanoma cell lines has been shown to overcome their resistance to BRAF and Hsp90 inhibitors (64), while BUB1 has been identified as a novel target downstream of SIRT1 in melanoma (65). Here, CDK2 is linked to melanoma.